Vivos Inc Implements Multiple Patient IsoPet® Therapy Day
21. April 2022 09:30 ET
|
Vivos Inc.
Richland WA, April 21, 2022 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce a combined IsoPet® therapy schedule into one treatment day, allowing for one production run...
Vivos Inc Initiates Isopet® Therapy in Horses
24. Juni 2021 09:30 ET
|
Vivos Inc.
Richland WA, June 24, 2021 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) Vivos Inc announced that it has completed the first IsoPet® therapy on an equoid tumor. It was administered at the University...
Vivos Inc Extends it Intellectual Property Protection
01. Dezember 2020 09:30 ET
|
Vivos Inc.
Richland WA, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc announced today that it received the Patent Cooperation Treaty (PCT) International Search Report on our patent...
Vivos Inc Successfully Treats Canine Sarcoma with IsoPet™ (RadioGel™)
31. Mai 2018 06:00 ET
|
Vivos Inc.
Richland, WA, May 31, 2018 (GLOBE NEWSWIRE) -- Vivos Inc (OTC: RDGL) successfully treated canine soft tissue sarcoma with its proprietary IsoPet™ (RadioGel™), a hydrogel liquid containing tiny...